Novartis Ag

Ciba-geigy Corporation

Benjamin B Mugrage

Leslie Wighton McQuire

John Henry Van Duzer

Roger A Fujimoto

Lauren Gilchrist Monovich

Daqiang Xu

Mahavir Prashad

David Thomas Parker

Wilhelm Kump

Sompong Wattanasin

John E Francis

Siem J Veenstra

Jen Chen

John H VanDuzer

Christian Borel

Compounds of formula (I) pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders. 

Phenylacetic acid derivatives

Compounds of formula (I) pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders. 

Certain phenylacetic acids and derivatives

Disclosed are the compounds of formula I wherein R is methyl or ethyl; Ris chloro or fluoro; Ris hydrogen or fluoro; Ris hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; Ris hydrogen or fluoro; and Ris chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.

Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

The invention relates to the 2-amino-7-(1-substituted-2-hydroxyethyl)-3, 5-dihydro-pyrrolo&lsqb;3,2-d&rsqb; pyrimidin-4-ones of formula I

2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo&lsqb;3,2-D&rsqb;pyrimidin-4-ones

The compounds of formula I ##STR1## wherein Ar represents biaryl, carbocyclic or heterocyclic aryl, are prepared, as substantially pure enantiomers, by

Preparation of 2-amino-7-(1-substituted-2-hydroxyethyl)-3,

The invention relates to the compounds of formula I ##STR1## wherein R is lower alkyl or hydrogen; R.sub.1 is hydrogen, lower alkyl or aryl-lower alkyl; R.sub.2 is hydrogen, nitro, cyano trifluoromethyl, halo, lower alkoxy, lower alkyl, lower alkoxycarbonyl, aminocarbonyl or mono- or di-lower alkylaminocarbonyl, amino or mono- or di-lower alkylamino; and pharmaceutically acceptable salts thereof when R.sub.1 is hydrogen; which are useful as endothelin antagonists.

Dihydropyridinecarboxylic acid anhydrides

The invention relates to novel acyl derivatives of rifamycins of the formula ##STR1## and the salts thereof, in which the structural elements --A.sub.1 --A.sub.2 --, --A.sub.3 --A.sub.4 -- and --A.sub.5 --A.sub.6 -- each denote ethylene or vinylene or the elements --A.sub.1 --A.sub.2 -- and --A.sub.3 --A.sub.4 -- each denote ethylene and --A.sub.5 --A.sub.6 -- denotes vinylene; X represents &gt;C(R.sub.6)-- or &gt;N-- and R.sub.6 denotes hydrogen or alkyl; alk denotes an aliphatic hydrocarbon radical; R.sub.1 denotes hydrogen or acyl; R.sub.2 denotes acyl, or alkyl which is optionally substituted by an aromatic radical, and R.sub.3 and R.sub.3 ' represent a common bond, or R.sub.3 denotes hydrogen or acyl, and R.sub.3 ' is hydrogen; R.sub.4 denotes hydrogen, cycloalkyl or aryl; R.sub.5 denotes hydrogen or acetyl; R.sub.7 denotes hydrogen or alkyl, which can be used as active compounds in medicaments, the preparation and use thereof, and pharmaceutical products and the preparation thereof.

Growing community of inventors

Voorhees, NJ, United States of America

Benjamin B Mugrage